PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Methods. Author manuscript; available in PMC 2013 February 1.
Published in final edited form as:
PMCID: PMC3261331
NIHMSID: NIHMS328029

IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery

Abstract

Interest in the application of advanced proteomics technologies to human blood plasma- or serum-based clinical samples for the purpose of discovering disease biomarkers continues to grow; however, the enormous dynamic range of protein concentrations in these types of samples (often >10 orders of magnitude) represents a significant analytical challenge, particularly for detecting low-abundance candidate biomarkers. In response, immunoaffinity separation methods for depleting multiple high- and moderate-abundance proteins have become key tools for enriching low-abundance proteins and enhancing detection of these proteins in plasma proteomics. Herein, we describe IgY14 and tandem IgY14-Supermix separation methods for removing 14 high-abundance and up to 60 moderate-abundance proteins, respectively, from human blood plasma and highlight their utility when combined with liquid chromatography-tandem mass spectrometry for interrogating the human plasma proteome.

Keywords: SuperMix, IgY14, immunoaffinity, plasma proteomics, Biomarker discovery

1. Introduction

Human bodily fluids, especially blood plasma and serum, that contain signature proteins relevant to most human diseases are widely utilized sample types for biomarker discovery [1, 2]. However, the ability to detect and identify specific) is often hampered by the “masking” effect caused by high-abundance proteins (HAP) that dominate these biofluids. For example, the 22 most abundant proteins in the human plasma proteome (in which protein concentrations span a dynamic range >10 orders of magnitude [3]) account for 99% of the total protein mass. Detection of candidate biomarkers present at ng/mL to pg/mL levels against a background of HAP that include albumin present at mg/mL levels is a formidable analytical challenge for current proteomics technologies. As a result, it is often necessary to separate or remove HAP and moderate-abundance proteins (MAP) from plasma/serum to enhance the detection of low-abundance proteins (LAP) and improve proteome coverage.

Immunoaffinity separations using immobilized antibodies have become the most commonly utilized strategies for removing HAP in blood plasma and serum. Affinity-purified polyclonal antibodies that are typically immobilized onto either chromatographic matrices or microbeads by cross-linking are used as immunoaffinity reagents to specifically remove target proteins [46]. Multiple HAP can be removed by optimizing a mixture of different antibody-immobilized beads within the partitioning column, as initially demonstrated by Piper et al. [4].

Many immunoaffinity products are now commercially available for simultaneous removal of multiple HAP from human plasma or serum. Most of these products are designed for single-stage separations that remove up to 20 HAP, depending upon the product. A multiple affinity removal system (MARS) from Agilent Technologies was one of the first immunoaffinity depletion systems to be commercialized. Initially, this product consisted of a mixture of polyclonal IgG antibodies to six HAP (serum albumin, IgG, IgA, transferrin, α-1-antitrypsin, and haptoglobin) attached to polymeric beads. Antibodies attached to the polymeric support through their Fc regions provide easy protein access to the affinity binding sites, and reported depletion efficiencies are >99% [7]. Later additions to the product line included a MARS-7 column that targets the original six proteins plus fibrinogen [810] and a MARS Hu-14 column that removes α1-acid glycoprotein, α2-macroglobulin, IgM, apolipoproteins A-I & A-II, complement C3, and pre-albumin in addition to the original six proteins and fibrinogen [10, 11]. Sigma-Aldrich offers the ProteoPrep® 20, which uses a mixture of polyclonal IgGs and single-chain antibodies to remove 20 HAP in human plasma/serum [12, 13].

A family of avian polyclonal immunoglobulin yolk (IgY) antibodies-based immunoaffinity products includes the Seppro® IgY developed by GenWay Biotech. The Seppro® IgY products (IgY12 and IgY14) consist of individual anti-HAP IgY beads blended to form mixtures that specifically remove either 12 or 14 HAP in human plasma with high reproducibility, as well as low-level binding of non-target proteins [5, 1416]. As immunoaffinity reagents, the IgY products have several advantages over IgG-based immunodepletion systems, including high affinity for HAP; less cross-reactivity to non-target proteins, which makes IgY antibodies more target-specific; target proteins are readily stripped from their cognate IgYs, which allows the IgY beads to be recycled multiple times; application to other mammalian proteomes due to a broader range of anti-human IgYs [3, 5, 1719].

While a number of single-stage immunoaffinity separation techniques have been demonstrated for removal of HAP [15], MAP remaining in the flow-through fraction still present a challenge for detection of LAP present at low ng/mL or even lower concentration levels. Recent application of a SuperMix column in tandem with an IgY12 column demonstrated removal of both HAP and MAP, effectively enriching LAP prior to proteomics analysis [6, 20]. A commercial IgY14 column is now available, which removes two additional abundant proteins (C3 and apoplipoprotein B) (Fig. 1A). Note, all Seppro® IgY immunodepletion products are currently available from Sigma-Aldrich in both bulk and liquid chromatography (LC) column formats.

Figure 1
The HAP and MAP distributions in the human blood plasma proteome. The top 14 HAP are targeted by the IgY14 column (A) and ~50 MAP are targeted by the SuperMix column. The percentage of protein abundances are based on spectral count data from LC-MS/MS ...

Herein, we present a brief overview of single-stage IgY14 and tandem IgY14-SuperMix immunoaffinity separations [6] as two of the most commonly applied strategies in proteomics-based biomarker discovery studies. Following the brief overview, we describe the detailed experimental protocols and highlight their utility in proteomics applications. While our applications exemplify the use of immunoaffinity separations in combination with LC-tandem mass spectrometry (MS/MS), in principle, these separations can be coupled with any downstream proteomics technologies for biomarker discovery or candidate verification.

2. Overview of IgY14 and SuperMix strategies

All analytical detection technologies including LC-MS have a limited dynamic range of detection. The range of protein concentrations in the human blood plasma spans >10 orders of magnitude, which is far greater than the dynamic range of detection afforded by LC-MS technologies (typically 4–5 orders of magnitude). As a result, strategies are necessary to reduce the range of protein concentrations and enhance the ability to detect LAP.

The IgY14 column is designed to remove the 14 most abundant proteins in human plasma that constitute 90–95% of the total protein mass (Fig. 1A). Individual IgY antibodies immobilized on microbeads against these 14 proteins are mixed in optimal amounts based on relative protein abundances to generate the stationary phase mixture for packing IgY14 columns. After loading a sample onto the column, >99% of the 14 abundant proteins are retained and then can be eluted as the bound fraction. MAP and LAP in the ‘depleted’ flow-through fraction are enriched by 10-fold for the same sample volume as the original sample. In other words, the dynamic range of protein concentrations in the depleted fraction is reduced by at least 10-fold.

The use of a SuperMix system to remove MAP (Fig. 1B) further enriches LAP. The column for this system is generated by using an IgY14-depleted plasma sample as a mixture of antigens to produce polyclonal IgY antibodies from immunized chickens. The IgY antibodies against MAP are purified using an antigen affinity column, after which the purified IgY antibodies are immobilized and packed into a SuperMix column (Fig. 2). When applied after IgY14 depletion, the SuperMix column captures an additional 50 or more MAP, The flow-through fraction contains mostly LAP in ~1% of the total starting plasma protein mass (Fig. 1B and Fig. 2). Collectively, tandem IgY14 and SuperMix separations provide ~100-fold enrichment of LAP in the flow-through fraction and at least two orders magnitude reduction in the dynamic range of protein concentrations. Application of these methods to enhance detection of LAP in blood plasma has been demonstrated for both human and mouse samples [6, 20].

Figure 2
The tandem IgY14-SuperMix immunoaffinity separation strategy. The SuperMix column is generated by using the protein mixture from IgY14-depleted human blood plasma as mixed antigens. For the tandem separations, plasma or other biofluid samples are initially ...

3. Experimental methods

3.1. Human blood plasma sample

Human plasma protein concentration is determined by BCA protein assay (Pierce), after which samples are diluted 5-fold with Tris Buffered Saline (TBS) that contains 10 mM Tris-HCl and 150 mM NaCl, pH 7.4. Samples may contain particulate materials that can be removed by using a 0.45 μm spin filter and centrifuging for 1 min at 9000× g. Unless otherwise noted, all protein sample processing is performed at 4 °C.

3.2. Generation of IgY14 and SuperMix LC columns

IgY antibodies (Seppro® IgY products), which were originally developed by GenWay Biotech, are now available from Sigma-Aldrich. To make these antibodies, purified human plasma proteins (> 96% purity) are introduced into laying hens as antigens and affinity ligands. The resulting antibodies are isolated from the egg yolks that provide a high-yielding reservoir of easy-to-access antibodies [5, 18]. The antibodies are purified through affinity columns prepared by coupling antigens to CNBr-activated Sepharose™ 4B (GE Healthcare), after which the affinity-purified IgY antibodies are conjugated to UltraLink Hydrazide Gel (Pierce). In the conjugation process, 2–5 mg/mL IgY antibodies in phosphate buffered saline (PBS) are oxidized with sodium periodate (NaIO4) for 30 min at room temperature. Once dialyzed against PBS to remove residual oxidant, the antibodies are coupled to UltraLink Hydrazide Gel microbeads at 4 °C overnight. IgY-coupled microbeads are then thoroughly washed with 1 M NaCl, followed by TBS, and stored as a 50% slurry in TBS with 0.01% NaN3 at 4 °C. The IgY immunodepletion column is prepared by blending individual anti-HAP IgY beads in optimal ratios based on the relative protein abundances of the 14 HAP in human plasm/serum.

The generation of a SuperMix column is similar to that of the IgY14 column. HAP in a plasma sample are initially depleted using an IgY14 affinity column, and the flow-through fraction (containing MAP and LAP) is then used to immunize chickens to generate a mixture of polyclonal IgY antibodies. As the IgY14-depleted flow-through fraction contains affinity ligands, the flow-through also is used to prepare an antigen affinity column for purifying antibodies from IgYs isolated from immunized chickens. Once purified, the mixture of IgY antibodies is conjugated to UltraLink Hydrazide Gel beads that are packed into an immunoaffinity column referred to as the SuperMix column (Fig. 2).

3.3. IgY14 and SuperMix immunoaffinity chromatography

3.3.1. Preparation of the LC system

IgY14 and SuperMix separations are performed using an Agilent 1100 series or similar type of LC system [15]. Most applications employ the IgY14 LC10 (10 mL bed volume) and the SuperMix LC5 (5 mL bed volume) columns. Overall protocols for using these columns generally follow the manufacturer’s (Sigma-Aldrich) instructions. The following three buffers diluted 10× from stock solutions are used as the mobile phases: 1) dilution buffer (TBS) – 10 ~ mM Tris-HCl, 150 mM NaCl, pH 7.4; 2) stripping buffer – 100 mM glycine, pH 2.5; and 3) neutralizing buffer – 100 mM Tris-HCl, pH 8.0. Before attaching the column to the LC systems it is important to purge lines with these three buffers and then run the dilution buffer at a flow rate of 2 mL/min to check the system backpressure. The operational pressure includes not only the pressure introduced by the column, but also the system backpressure from the instrument. Note, the pressure introduced by the column is usually < 4 bar. Following attachment of the immunoaffinity separation column to the LC system, equilibrate the column with the dilution buffer for 20 min at a flow-rate of 2 mL/min to obtain a flat baseline, all the while monitoring at 280 nm. Two blank runs are then performed by injecting 500 μL of dilution buffer.

3.3.2. IgY14 LC10 separations

While the IgY14 LC10 column has a capacity for up to 250 μL human plasma or serum, based on our experience it is better to load 200 μL or less to avoid over-loading. The IgY14 LC10 separation consists of five steps (i.e., sample loading, washing, eluting, neutralization, and re-equilibration). The total cycle time using an Agilent 1100 series HPLC system is ~60 min [6, 15]. Up to 930 μL diluted and filtered sample (containing up to 185 μL original plasma) is injected onto the IgY14 LC-10 column at a flow rate of 0.5 mL/min for 20 min, after which the column is washed with the dilution buffer at a flow rate of 2.0 mL/min for 5 min. The IgY14 flow-through fraction is collected and stored at −80 °C until analysis. Bound proteins are eluted from the column using the stripping buffer at a flow rate of 2.0 mL/min for 15 min and collected as the IgY14 bound fraction. The column is then neutralized using the neutralizing buffer at a flow rate of 2.0 mL/min for 10 min and re-equilibrated with the dilution buffer at 2.0 mL/min for 10 min. The re-equilibrated column is ready for the next injection or may be stored at 4 °C in the dilution buffer that contains 0.02% sodium azide.

Following the IgY14 separations, the flow-through and bound fractions can be concentrated using Amicon® Ultra-15 (5 kDa nominal molecular weight limit, Millipore, Billerica, MA) concentrators followed by buffer exchange to 50 mM NH4HCO3 (pH 8.0). Protein concentrations can then be determined by BCA protein assay (Pierce).

3.3.3. SuperMix LC5 separations

The concentrated IgY14 flow-through fraction can be subjected further to SuperMix LC5 partitioning on the same HPLC system in an off-line mode [6]. The separation procedures on the SuperMix LC5 column are similar to those described above for the IgY14 LC10 separation [6, 15]. Both the flow-through and bound fractions from the SuperMix column are collected and concentrated with buffer exchange to 50 mM NH4HCO3.

3.3.4. On-line tandem IgY14-SuperMix separations

By introducing a six-port control valve to couple the two columns, automated tandem IgY14 LC10 and SuperMix LC5 separations can be performed (Fig. 3) [20]. The IgY14 and SuperMix LC5 columns connected by the six-port valve (Agilent, Santa Clara, CA) allow the plasma sample to pass through both columns following injection. Positions 3 and 5 on the valve are plugged to prohibit back-flush towards the waste or columns during valve switching. A tee union allows the liquid stream from the IgY14 or IgY14-SuperMix column to be directed towards the UV detector and subsequently towards the fraction collector. This configuration allows collection of the SuperMix flow-through and bound portions, as well as IgY14 bound portion in different fractions, and significantly improves the overall throughput and reproducibility of the tandem IgY-SuperMix immunodepletion systems [20].

Figure 3
The IgY14-SuperMix separation strategy with the tandem connection mode. (A) IgY14 and SuperMix columns are connected to ports 1 and 2 of a six-port valve. Port 1 is connected to port 2 when human blood plasma sample is injected into the columns. The flow-through ...

Loading a diluted plasma or serum sample onto the tandem IgY14 and SuperMix separation system is performed using 1× dilution buffer at a flow rate of 0.5 mL/min for 45 min to obtain the flow-through fractions from both columns (Fig. 3A). Afterwards, the IgY14 bound proteins are eluted by passing the stripping buffer to only the IgY14 column at a flow rate of 2.0 mL/min for 15 min and collected as the IgY14 bound fraction (Fig. 3B). The stripping buffer is then passed through to both columns at a flow rate of 1.0 mL/min for 20 min to elute the SuperMix bound fraction (Fig. 3C). Both columns are subsequently neutralized by passing neutralization buffer through at 1 mL/min for 20 min, and re-equilibrated with dilution buffer at 1 mL/min for 20 min for a total cycle time of 120 min. All collected fractions are concentrated in Amicon Ultra-15 concentrators followed by buffer exchange to 50 mM NH4HCO3 at pH 8.0.

3.3 Downstream proteomics analysis

Protein samples in the collected bound and flow-through fractions are amenable to downstream processing and proteomics analyses with various technologies. In the case of LC-MS/MS proteomics profiling, protein samples are typically subjected to trypsin digestion, and the resulting peptide samples are analyzed by LC-MS/MS, using ion-trap mass spectrometers as previously described [6]. In 2D-LC-MS/MS, strong cation exchange chromatography is applied for initial peptide fractionation prior to LC-MS/MS analyses. Peptides are identified by using SEQUEST or Mascot algorithms [6] to search MS/MS spectra against a pre-established human protein database. In our previous study, we employed static carboxamidomethylation of cysteine and dynamic oxidation of methionine criteria for the database search [6]. The false discovery rate of peptide identifications can be estimated by using an established decoy database searching methodology [21] and filtering criteria are applied to control the false discovery rate to be <5% at the unique peptide level.

4. Proteomics applications of IgY14 and SuperMix separations

In principle immunoaffinity separations can be coupled with a variety of different proteomics technologies to enable broad proteomics applications. We note that some of the data presented in the following applications were obtained using an IgY12 column, as at the time of study, the IgY14 column had not yet been placed on the market [6]. Regardless, the results from the original study performed with the IgY12 column demonstrate the enhancement in LAP afforded by the SuperMix depletion, as well as overall reproducibility of the separation systems.

4.1. Enhanced coverage of LAP by SuperMix separations

A comprehensive list of proteins identified previously using 1D- and 2D-LC-MS/MS analyses [6] allows us to illustrate the enhanced LAP coverage achieved with the SuperMix separation. In a head-to-head comparison of the proteome coverage between IgY12 and SuperMix flow-through samples, ~64% and ~83% more proteins were identified in the SuperMix flow-through fraction in 1D- and 2D-LC-MS/MS analyses, respectively, than in than in the IgY12 flow-through fraction. Moreover, tandem IgY12-Supermix separations coupled with 2D-LC-MS/MS allowed identification of more LAP in human plasma with literature-reported concentrations below 100 ng/mL than did a single stage IGY12 separation, including identification of M-CSF and MMP8 that have ELISA-validated concentrations of 202 pg/mL and 12.4 ng/mL, respectively (See Fig. 4) [6]. These results clearly show that the use of tandem IgY12-SuperMix separations offers significant enhancements in detection of LAP and overall proteome coverage.

Figure 4
The 40 low-abundance plasma proteins detected in 2D-LC-MS/MS analyses of SuperMix flow-through. The protein concentration is plotted on a log scale. All proteins were reported to have a normal concentration <100 ng/mL; only 21 detected by IgY-12. ...

4.2. Reproducibility of IgY and tandem IgY-SuperMix separations

Both IgY12 [15] and tandem IgY12-SuperMix separations have proven reproducible [6], which is particularly important for quantitative applications in clinical proteomics. Good reproducibility was evident in immunoaffinity HPLC traces of tandem IgY14-SuperMix depletion for analyses of a quality control plasma sample obtained during early, middle, and late stage of the column life, respectively (Fig. 3D). Moreover, technical LC-MS/MS replicate analyses also demonstrated the reproducibility of the overall process based on the number of MS/MS spectra (“spectral count”) that identify a given protein as shown in Fig. 5. Our experience over the past several years indicates that IgY12, IgY14 and SuperMix columns typically allow 100–150 reproducible separations within an approximate two-year shelf-life span.

Figure 5
Reproducibility of the tandem IgY12-SuperMix separations evaluated by LC-MS/MS. Reproducibility of three replicates of the tandem IgY12-SuperMix separations were assessed based on spectral count information of identified proteins from individual LC-MS/MS. ...

Quality control analyses of a standard human plasma sample should be performed routinely to assess reproducibility of immunoaffinity separations over the column life time. The intensity ratios between three peaks (as shown in the chromatograms in Fig. 3D), as well as peak shapes and peak elution times, which should be reproducible over the column life-time, are used as the parameters for assessing column performance. We have typically observed rapid deterioration of peak shapes and elution times when > 100 separations are performed on a given column, an indicator that column performance was no longer acceptable.

4.3. Capture efficiency for HAP and MAP

The capture efficiency of the IgY12 and SuperMix columns for HAP and MAP can be estimated based on the observed spectral counts of target proteins from triplicate LC-MS/MS analyses of both bound and flow-through fractions. This estimation allows identification of target proteins that are efficiently captured by the column because either none or a minimum number of spectral counts should be observed in the flow-through fraction [6]. For example, we observed 45 MAP captured by the SuperMix column with >90% efficiency (Table 1), with ~35 additional proteins captured with 20–90% efficiency.

Table 1
List of moderate-abundance proteins efficiently captured by the SuperMix column*.

4.4. Perspective on high throughput applications

Both IgY14 and tandem IgY14-SuperMix immunodepletion strategies offer an effective way to dig deeper into complex biofluid proteomes for quantitative clinical applications. Unlike other fractionation approaches that typically produce many fractions, the immunoaffinity separations only generate two (i.e., flow-through and bound) fractions with the added benefit of increased analytical throughput. Both single-stage IgY14 and tandem IgY14-SuperMix separations can be fully automated on an HPLC system to enable the processing of many samples [20, 22].

With a shelf-life of at least two years and capability for 100–150 separations per immunoaffinity column, column-to-column variations in a given large-scale study are minimized. We note that potential column-to-column variations have not been well studied to date and that such assessment would necessary if a large-scale study involving several thousands of samples were to be performed using such technologies. However, given the observed overall good reproducibility of immunoaffinity separations, the IgY14 and IgY14-SuperMix strategies can be effectively coupled with downstream quantitative proteomics analyses for biomarker discovery, as well as for candidate biomarker verification. Different quantitative approaches such as label-free [23], spectral counting [24], O16/O18 labeling [25, 26], iTRAQ labeling [27], and targeted quantification using LC-SRM-MS coupled with stable isotope dilution [8, 28] are all applicable and the choice of which to use would depend on the study design.

4.5. Potential pitfalls

While tandem IgY14-SuperMix immunoaffinity separations have been demonstrated effective for a range of applications, there are several potential pitfalls associated with the immunoaffinity methods that should be noted. First, a general concern for immunoaffinity strategies is the potential loss of target proteins caused by non-specific binding of non-targeted proteins to the affinity matrices or by physiologically relevant interactions between targeted and non-targeted proteins [15, 2933]. In the case of SuperMix partitioning, the column contains an undefined mixture of antibodies in differing amounts. We anticipate that many proteins may partially bind to the column due to the presence of antibodies, as well as to interactions with other MAP and LAP. Therefore, we suggest that the use of the SuperMix column be considered as a fractionation scheme rather than a depletion scheme so that all proteins will be recovered in either the bound or flow-through fractions. In the case of partial binding to the columns, we have demonstrated that the extent of nonspecific or specific binding for a given protein is reproducible and quantifiable [6, 15].

Another valid concern is that LAP in the bound fraction will be difficult to detect due to the masking effects of the MAP, even if both bound and flow-through fractions are analyzed. Because of the high complexity of antibodies in the SuperMix column, we expect that some LAP of interest are partitioned predominantly to the bound fraction. In such scenarios, one might apply both single stage IgY14 separations and tandem IgY14-SuperMix separations as these two approaches afford complementary detection of LAP.

5. Concluding remarks

Enabling the removal of HAP and MAP from human biofluids, multi-component immunoaffinity separations on HPLC systems have become powerful tools for biomarker discovery studies. A number of immunoaffinity LC columns with either IgG or IgY antibodies are commercially available for removing 6 to 20 HAP in human plasma/serum depending upon the application needs. Furthermore, both HAP and MAP can be removed by applying IgY14 and SuperMix columns in tandem, which significantly improves detection of LAP and the overall proteome coverage compared to previously reported immunoaffinity separation strategies. Both single-stage and tandem IgY14-SuperMix separations are reproducible and automatable on an HPLC system, making them feasible strategies for large-scale discovery or candidate biomarker verification applications. Moreover, these strategies can be readily integrated with any downstream LC-MS-based or gel-based approaches for protein identification and/or quantification. As a result, both single-stage and tandem IgY14-SuperMix strategies are anticipated to have broad applications in candidate disease biomarker discovery and verification studies with human biofluids.

  • Immunoaffinity separations are key tools for enriching low-abundance proteins.
  • Methods for IgY14 and SuperMix Immunoaffinity separations are described.
  • IgY14 separation removes the top 14 abundant proteins from human plasma.
  • Tandem IgY14-SuperMix separations remove up to 60 abundant proteins.
  • Proteomics applications of IgY14 and SuperMix separations are highlighted.

Acknowledgments

Portions of this work were supported by the NIH Director’s New Innovator Award Program 1-DP2OD006668-01, NIH grants R01 DK074795, CA111244, and RR018522. The experimental work described herein was performed in the Environmental Molecular Sciences Laboratory, a national scientific user facility sponsored by the U. S. Department of Energy (DOE)/BER and located at Pacific Northwest National Laboratory, which is operated by Battelle Memorial Institute for the DOE under Contract DE-AC05-76RL0 1830.

Abbreviations

HAP
high-abundance proteins
MAP
moderate-abundance proteins
LAP
low-abundance proteins
HSA
human serum albumin
IgG
Immunoglobulin G
SRM
selected reaction monitoring
SID
stable isotope dilution
MARS
multiple affinity removal system
IgY
immunoglobulin yolk
LC
liquid chromatography
MS
mass spectrometry

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Lathrop JT, Anderson NL, Anderson NG, Hammond DJ. Curr Opin Mol Ther. 2003;5:250–257. [PubMed]
2. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A. Mol Cell Proteomics. 2004;3:311–326. [PubMed]
3. Anderson NL, Anderson NG. Mol Cell Proteomics. 2002;1:845–867. [PubMed]
4. Pieper R, Su Q, Gatlin CL, Huang ST, Anderson NL, Steiner S. Proteomics. 2003;3:422–432. [PubMed]
5. Huang L, Harvie G, Feitelson JS, Gramatikoff K, Herold DA, Allen DL, Amunngama R, Hagler RA, Pisano MR, Zhang WW, Fang X. Proteomics. 2005;5:3314–3328. [PubMed]
6. Qian WJ, Kaleta DT, Petritis BO, Jiang H, Liu T, Zhang X, Mottaz HM, Varnum SM, Camp DG, 2nd, Huang L, Fang X, Zhang WW, Smith RD. Mol Cell Proteomics. 2008;7:1963–1973. [PMC free article] [PubMed]
7. Brand J, Haslberger T, Zolg W, Pestlin G, Palme S. Proteomics. 2006;6:3236–3242. [PubMed]
8. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Mol Cell Proteomics. 2007;6:2212–2229. [PMC free article] [PubMed]
9. Pernemalm M, Lewensohn R, Lehtio J. Proteomics. 2009;9:1420–1427. [PubMed]
10. Tu C, Rudnick PA, Martinez MY, Cheek KL, Stein SE, Slebos RJ, Liebler DC. J Proteome Res. 2010;9:4982–4991. [PMC free article] [PubMed]
11. Zolotarjova N, Mrozinski P, Chen H, Martosella J. J Chromatogr A. 2008;1189:332–338. [PubMed]
12. Schuchard MD, Melm CD, Crawford AS, Chapman HA, Cockrill SL, Ray KB, Mehigh RJ, Kappel WK, Scott GB. Origins. 2005;21:17–23.
13. Herosimczyk A, Dejeans N, Sayd T, Ozgo M, Skrzypczak WF, Mazur A. Physiol Pharmacol J. 2006;57(Suppl 7):81–93. [PubMed]
14. Fang X, Huang L, Feitelson JS, Zhang WW. Drug Discov Today Technol. 2004;1:141–148. [PubMed]
15. Liu T, Qian WJ, Mottaz HM, Gritsenko MA, Norbeck AD, Moore RJ, Purvine SO, Camp DG, 2nd, Smith RD. Mol Cell Proteomics. 2006;5:2167–2174. [PMC free article] [PubMed]
16. Bandow JE. Proteomics. 2010;10:1416–1425. [PubMed]
17. Hinerfeld D, Innamorati D, Pirro J, Tam SW. J Biomol Tech. 2004;15:184–190. [PMC free article] [PubMed]
18. Huang L, Fang X. Methods Mol Biol. 2008;425:41–51. [PubMed]
19. Fang X, Zhang WW. J Proteomics. 2008;71:284–303. [PubMed]
20. Zhou JY, Petritis BO, Petritis K, Norbeck AD, Weitz KK, Moore RJ, Camp DG, Kulkarni RN, Smith RD, Qian WJ. J Proteome Res. 2009;8:5387–5395. [PMC free article] [PubMed]
21. Qian WJ, Liu T, Monroe ME, Strittmatter EF, Jacobs JM, Kangas LJ, Petritis K, Camp DG, Smith RD. J Proteome Res. 2005;4:53–62. [PubMed]
22. Juhasz P, Lynch M, Sethuraman M, Campbell J, Hines W, Paniagua M, Song L, Kulkarni M, Adourian A, Guo Y, Li X, Martin S, Gordon N. J Proteome Res. 2011;10:34–45. [PubMed]
23. Wang W, Zhou H, Lin H, Roy S, Shaler TA, Hill LR, Norton S, Kumar P, Anderle M, Becker CH. Anal Chem. 2003;75:4818–4826. [PubMed]
24. Liu H, Sadygov RG, Yates JR., 3rd Anal Chem. 2004;76:4193–4201. [PubMed]
25. Qian WJ, Monroe ME, Liu T, Jacobs JM, Anderson GA, Shen Y, Moore RJ, Anderson DJ, Zhang R, Calvano SE, Lowry SF, Xiao W, Moldawer LL, Davis RW, Tompkins RG, Camp DG, 2nd, Smith RD. Mol Cell Proteomics. 2005;4:700–709. [PMC free article] [PubMed]
26. Qian WJ, Petritis BO, Kaushal A, Finnerty CC, Jeschke MG, Monroe ME, Moore RJ, Schepmoes AA, Xiao W, Moldawer LL, Davis RW, Tompkins RG, Herndon DN, Camp DG, 2nd, Smith RD. Journal of proteome research. 2010;9:4779–4789. [PMC free article] [PubMed]
27. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. Mol Cell Proteomics. 2004;3:1154–1169. [PubMed]
28. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SA. Clin Chem. 2009;55:1108–1117. [PMC free article] [PubMed]
29. Granger J, Siddiqui J, Copeland S, Remick D. Proteomics. 2005;5:4713–4718. [PubMed]
30. Gong Y, Li X, Yang B, Ying W, Li D, Zhang Y, Dai S, Cai Y, Wang J, He F, Qian X. J Proteome Res. 2006;5:1379–1387. [PubMed]
31. Yocum AK, Yu K, Oe T, Blair IA. J Proteome Res. 2005;4:1722–1731. [PubMed]
32. Zhou M, Lucas DA, Chan KC, Issaq HJ, Petricoin EF, 3rd, Liotta LA, Veenstra TD, Conrads TP. Electrophoresis. 2004;25:1289–1298. [PubMed]
33. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Araujo RP, Hood BL, Veenstra TD, Conrads TP, Goldsmith P, Fishman D, Petricoin EF, 3rd, Liotta LA. Clin Chem. 2005;51:1933–1945. [PubMed]